stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Net income
Halozyme Therapeutics, Inc.'s net income for fiscal 2025 was $316.9M, down 28.6% from $444.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $485.4M. Over the past ten years it has ranged from −$103.0M (fiscal 2016) to $444.1M (fiscal 2024); the current reading is higher than 82% of that period. Halozyme Therapeutics, Inc. ranks 12th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $316.9M | (28.64%) |
| FY2024 | $444.1M | 57.71% |
| FY2023 | $281.6M | 39.31% |
| FY2022 | $202.1M | (49.81%) |
| FY2021 | $402.7M | 211.97% |
| FY2020 | $129.1M | — |
| FY2019 | −$72.2M | — |
| FY2018 | −$80.3M | — |
| FY2017 | $63.0M | — |
| FY2016 | −$103.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $247.0M | 7.45% |
| Jun 2026 | $229.9M | 53.23% |
| Mar 2026 | $150.0M | — |
| Dec 2025 | −$141.6M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| EXEL Exelixis, Inc. compare | $885.1M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| HALO Halozyme Therapeutics, Inc. | $485.4M |
| JAZZ Jazz Pharmaceuticals PLC compare | $206.0M |
| TECH Bio-Techne Corp compare | $181.9M |
| BMRN BioMarin Pharmaceutical Inc. compare | −$19.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$349.4M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on HALO
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement